March 11, 2025

FDA's New Pulse Oximeter Guidance: Stricter Standards, Ongoing Challenges

The FDA's 2025 pulse oximetry guidance introduces stricter accuracy standards, larger study cohorts, and objective skin pigmentation assessment to address measurement bias in darker-skinned patients.

Conexiant

March 11, 2025

Doctors Never Truly Vacation, Study Reveals

"Organizations should implement strategies to minimize clinical tasks during PTO."

Conexiant

March 10, 2025

AI Methods Strengthen Real-World Data Reliability

Researchers assessed the impact of AI-driven methods on real-world data reliability, showing improvements in accuracy, completeness, and traceability

Conexiant

March 10, 2025

New Bispecific Antibodies Neutralize SARS-CoV-2 Variants

Researchers develop dual-targeting antibodies that maintain potency against Omicron sublineages, including XBB.1.5, BA.2.86, and JN.1

Conexiant

March 10, 2025

Study: Night Shifts Increase Infection Rates

Health care workers with more than 2 hours of sleep debt face significantly higher odds of respiratory and gastrointestinal illnesses.

Conexiant

March 07, 2025

FDA Approves First Xolair Biosimilar

New interchangeable treatment option Omlyclo now available for patients with allergic asthma, chronic hives, nasal polyps, and food allergies; carries same boxed warning for anaphylaxis as original medication.

Conexiant

March 07, 2025

Nationwide Study Reveals Key Trends in Pediatric Pulmonary Embolism

Pediatric patients with acute pulmonary embolism had a 9.3 times higher crude odds ratio for in-hospital death compared with those without PE, a new study finds.

Conexiant

March 06, 2025

Younger Age, Active SLE, Prednisone Tied to Pericarditis Recurrence

Researchers found that younger age, active systemic lupus erythematosus, and prednisone use significantly increase the risk of recurrent pericarditis in lupus patients.

Conexiant

March 06, 2025

Tezepelumab Shows Promise for Severe CRSwNP in Phase 3 Trial

The WAYPOINT trial provides strong evidence that tezepelumab effectively reduces nasal polyp size, congestion, and overall symptom burden in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps

Conexiant